Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine for CVD Risk Factors
NCT03770325Phase 3Completed
- Sponsor
- The University of Hong Kong
- Start
- Apr 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyperlipidemia comparing Berberine with Placebo (2 arms). Primary endpoints: Lipid profile at 12 weeks, Blood pressure at 12 weeks and 9 more. Started Apr 2019; status: completed.
02
Drugs
berberine
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT03770325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03770325.